| Mitotane is a drug of choice for cancer of the adrenal gland. It is administered in tablet dosage form with the very high dose of 4–6 g/day. |
| Because of poor water solubility and low bioavailability, mitotane has a unpredictable pharmacokinetic profile resulting in high inter-/intra-individual variability and severe adverse effects. |
| It is hypothesized that the transformation of oral mitotane to an injectable form could potentially circumvent the major problems while providing better control over mitotane plasma concentrations and overall improving the therapeutic outcomes. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.